The US International Trade Commission has ended the long-running dispute over blood oxygen monitoring on the Apple Watch. Apple has been in legal hot water with rival Masimo, which claimed to own the patents behind the tech, since it added blood oxygen monitoring to the Apple Watch Series 6 in 2020. The smaller company accused Apple of stealing trade secrets to build the health feature.
Apple managed to have all but two of the 17 patents invalidated in September 2023, but despite that, in December 2023, the U.S. International Trade Commission (ITC) upheld a ruling stating that Apple violated Masimo’s patent, which partially halted sales of the Apple Watch 9 and Apple Watch Ultra 2.
Article continues below
What does this mean for Apple Watch wearers?
The ruling terminates the case, which means Apple can now sell models with a redesigned blood oxygen sensor in the United States. It’s not clear whether Apple will roll out an update to allow existing Apple Watch wearers to see SpO2 readings on their devices themselves, or whether this ruling will only change future devices on sale in the US.